Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The poliovirus capsid protein complex is the viral protein shell that surrounds and protects the single-stranded RNA genome of poliovirus. It consists of 60 copies each of four structural proteins: VP1, VP2, VP3, and VP4, assembled into an icosahedral structure[1][2][3][5]. VP1, VP2, and VP3 form the outer surface, while VP4 is located internally. The capsid surface mediates attachment to the host cellular receptor, poliovirus receptor (PVR/CD155), triggering conformational changes required for cell entry and genome release[1][2][6]. Mutations in the capsid proteins affect viral stability, receptor usage, and susceptibility to antivirals, making the capsid a key therapeutic target in antiviral drug development and vaccine design[4][6]. The complex is not a human protein, but a viral assembly, and serves as a major determinant of viral infectivity and host immune recognition[1][3][5].
Inhibition of capsid-receptor interaction and uncoating Stabilization of the capsid to prevent conformational change required for viral RNA release
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus capsid protein complex (VP1–VP4).